pembrolizumab,cemiplimab,nivolumab,cabozantinib,ipilimumab
merck,bms,sanofi,regeneron
['nivolumab', 'pembro', 'cemiplimab', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'imab ']
ici in penile ca? by retrospective study: 90% w metastatic disease, 10% w locally advanced 80% pts w prior therapy pfs 3.2mo, os 9.8mo, orr 13% need translational studies to identify pts that are most likely to benefit, hpv status not predictive
#gu23 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast